Viral Vector– tag –
-
Catalent Expands AAV Gene Therapy Partnership with Taysha Gene Therapies, Securing Exclusive Commercial Manufacturing for Rett Syndrome Treatment TSHA-102
Pharma Manufacturing USA Overview Taysha Gene Therapies and CDMO Catalent have expanded their strategic partnership, designating Catalent as the exclusive commercial manufacturer for TSHA-102, an AAV-based gene therapy for Rett syndrome,... -
Promises and Pitfalls of In Vivo CAR Gene Therapy: Clinical Proof-of-Concept Progresses Amidst Focus on Safety and Biological Factors
Blood - ASH Publications USA Overview While ex vivo CAR-T cell therapies demonstrate high efficacy in lymphoid hematologic malignancies, their logistical complexity and high costs limit patient access. In contrast, in vivo CAR gene thera... -
CRISPR Gene Editing Therapies Limited to Ex Vivo Approvals for Sickle Cell and Beta-Thalassemia in 2026; In Vivo Candidates Show 87% Attack Reduction and 62% Cholesterol Decrease
DeepDNA USA Overview As of August 2026, the only globally approved CRISPR gene-editing therapies are ex vivo treatments for sickle cell disease and transfusion-dependent beta-thalassemia. However, in vivo therapies are demonstrating sign... -
Cell & Gene Therapy Manufacturing Faces Deepening Bottlenecks: AmplifyBio, Exothera Close; Thermo Fisher Cuts Viral Vector Jobs, but FDA Eases Regulations to Support Growth
Endpoints News Global Overview Despite cell and gene therapies becoming a commercial reality, manufacturing remains the primary bottleneck. The CDMO sector is struggling with overcapacity and underfunding, leading to closures like Amplif... -
Heart-Specific LNP Delivery for Myocardial Infarction Remains a Challenge: Conventional LNPs Accumulate in Liver, while Novel Lipid Engineering Targets Lungs and Spleen
American Heart Association Journals USA Overview Lipid nanoparticles (LNPs) are clinically validated non-viral vectors for delivering therapeutics like small molecules, mRNA, and siRNA; however, achieving heart-specific drug delivery for... -
Non-Endocytic Membrane-Translocating Delivery Strategies Bypass Endosomal Barriers for Gene, mRNA, and Protein Therapies
Drug Target Review UK Overview A new review evaluates non-endocytic membrane-translocating delivery strategies designed to circumvent insufficient endosomal escape efficiency, a major hurdle for many next-generation therapeutics. These e... -
LNP-Mediated Gene Therapy to Correct ACTA2 Mutations Shows Promise: Reduces Stroke-Related Mortality, Offers Re-dosability & Lower Costs Over Viral Vectors
MSMDS.org USA Overview A novel lipid nanoparticle (LNP)-based gene therapy strategy is under development to correct ACTA2 mutations in vascular smooth muscle cells. This approach offers significant advantages over viral vectors, includin... -
BioPharma Dive Reports on Cell and Gene Therapy Manufacturing Frontlines: Viral Vector Supply Shortages and CDMO Market Soaring to $9.08 Billion by 2031
BioPharma Dive USA Overview BioPharma Dive analyzes key challenges and commercial opportunities in cell and gene therapy manufacturing, pinpointing viral vector production as the most severe supply constraint. Lonza is significantly expa... -
CHOC Shapes Future of Pediatric Gene Therapy: Driving Early Intervention with CRISPR Editing and Strict Quality Control
Children's Hospital of Orange County (CHOC) Pediatrica USA Overview Rady Children's Health Orange County is focusing on in vivo gene replacement, ex vivo gene therapy (e.g., CAR T-cell therapy), and CRISPR-based genome editing to shape t... -
ProBio Opens $25 Million Plasmid & Viral Vector Center of Excellence in Hopewell, New Jersey, Creating Over 100 Highly Skilled Jobs
New Jersey Business Magazine USA Overview ProBio has inaugurated a $25 million, 128,000-square-foot Plasmid & Viral Vector Center of Excellence in Hopewell, New Jersey, significantly bolstering its production capabilities for cell an...
